Results of Operations and Financial Condition. On August 6, 2026, Ardelyx, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 2.02, including Exhibit 99.1 hereto, shall not be considered “filed” under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), no…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On June 29, 2026, Ardelyx, Inc. (the “Company”) received $50.0 million of funding (the “Term F Loan”) pursuant to the loan and security agreement entered into in February 2022 by and between the Company and SLR Investment Corp., as collateral agent (the “Agent”) and the lenders listed in the agreement (collectively, the “Lenders”), as amended in August 2022, February 2023, Octobe…

The filing pertains to the approval of an equity incentive plan amendment, not a management change.

Results of Operations and Financial Condition. On April 30, 2026, Ardelyx, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 2.02, including Exhibit 99.1 hereto, shall not be considered “filed” under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), n…

Results of Operations and Financial Condition. On February 19, 2026, Ardelyx, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 2.02, including Exhibit 99.1 hereto, shall not be considered “filed” under the Securities Exchange Act of 1934, as amended (the “Ex…

Results of Operations and Financial Condition. On January 8, 2026, Ardelyx, Inc. (the “Company”) announced: • Unaudited U.S. net product sales revenue of IBSRELA ® (tenapanor) of approximately $87 million for the fourth quarter ended December 31, 2025, and approximately $274 million for the full year ended December 31, 2025. • Unaudited U.S. net product sales revenue of XPHOZAH ® (tenapanor) of approximately $28 million for the fourth quarter ended December 31, 2025, and approximately $104 mi…

Chief Legal and Administrative Officer — Elizabeth Grammer: Elizabeth Grammer resigned from her executive role but will continue in a non-executive position and as a Senior Advisor.

shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

CFO — Sue Hohenleitner: The company hired a new CFO from an external source with significant experience.

shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

Chief Financial and Operations Officer — Justin Renz: Mr. Renz is transitioning out of his role as Chief Financial and Operations Officer.

Entry into a Material Definitive Agreement. On June 30, 2025, Ardelyx, Inc. (the “Company”) entered into a Fifth Amendment (the “Fifth Amendment”) to the Loan and Security Agreement, dated February 23, 2022, by and among the Company, as borrower, SLR Investment Corp. (“SLR”), as collateral agent and the lenders party thereto. The Fifth Amendment, among other things, (1) provided for the immediate draw of the principal amount of $50.0 million (the “Term E Loan”) on the closing date of the Fift…

The filing pertains to the approval of an amendment to the equity incentive award plan, which is not a management change event.

shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

Director — Merdad Parsey, M.D., Ph.D.: Dr. Merdad Parsey was appointed as a Class I director and to the Nominating and Corporate Governance Committee.

shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

Results of Operations and Financial Condition. On January 13, 2025, Ardelyx, Inc. (the “Company”) announced: • Unaudited U.S. net product sales revenue of IBSRELA ® (tenapanor) of approximately $54 million for the fourth quarter ended December 31, 2024, and approximately $158 million for the full year ended December 31, 2024. • Unaudited U.S. net product sales revenue of XPHOZAH ® (tenapanor) of approximately $57 million for the fourth quarter ended December 31, 2024, and approximately $161 m…

Principal Accounting Officer — Joseph Reilly: Joseph Reilly was promoted to Principal Accounting Officer, replacing Robert Felsch.

shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

Entry into a Material Definitive Agreement. On October 3, 2024, Ardelyx, Inc. (the “Company”) and BMR-Pacific Research Center LP (the “Landlord”) entered into a Lease Agreement (the “New Fremont Lease”) whereby the Company will lease approximately 15,000 square feet on the first floor (the “New Fremont Premises”) of the building located at 7999 Gateway Boulevard, Newark, California. The initial term of the New Fremont Lease will be thirty-nine (39) months and the Company will have one (1) opt…

Entry into a Material Definitive Agreement. On On August 7, 2024, Ardelyx, Inc. (the “Company”) entered into a Commercial Supply Agreement (the “Supply Agreement”) with Catalent Pharma Solutions, LLC (“Catalent”). The Supply Agreement is effective as of July 23, 2024. The Supply Agreement provides that Catalent will perform tableting, testing, release and bulk packaging of IBSRELA® (“Product”) in accordance with the specifications, target yields, and other terms and conditions set forth in th…

shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

The filing pertains to the approval of amendments and restatements of equity incentive plans, which are routine corporate actions.

shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On March 1, 2024, Ardelyx, Inc. (the we, us, our) received $50.0 million of funding (Term C Loan) pursuant to the loan and security agreement entered into in February 2022 by and between us and SLR Investment Corp. as collateral agent (Agent) and the lenders listed in the agreement (collectively, the Lenders), and as amended in August 2022, February 2023 and October 2023 (collect…